Full-Time

Associate Clinical Project Manager

Posted on 5/9/2026

LivaNova

LivaNova

1,001-5,000 employees

Global cardiopulmonary and neuromodulation devices

Compensation Overview

$95k - $105k/yr

+ Bonus

Remote in USA + 10 more

More locations: Boston, MA, USA | Houston, TX, USA | Austin, TX, USA | Dallas, TX, USA | Chicago, IL, USA | Charlotte, NC, USA | Phoenix, AZ, USA | Minneapolis, MN, USA | Denver, CO, USA | Atlanta, GA, USA

Hybrid

Category
Business & Strategy (1)
Required Skills
Risk Management
Google Cloud Platform
Requirements
  • Minimum 4+ years of prior work experience as a Clinical Research Nurse or equivalent role supporting clinical trial project management at a medical device or drug company, clinical research site, or contract research organization.
  • Knowledge of international regulations and guidelines (ISO14155 and Good Clinical Practice) and clinical study design and implementation.
  • Working knowledge of medical terminology.
  • Capability and willingness to learn device function.
  • Ability to interface effectively with medical professionals.
  • Strong analytical and organizational skills, with excellent attention to detail and accuracy.
  • Project oversight and tracking capability.
  • Good oral and written communication skills.
  • Ability to work autonomously with excellent organizational skills and ability to prioritize assignments while handling various projects simultaneously.
  • Experience with electronic data capture (EDC) and clinical trial management systems (CTMS).
  • Demonstrated ability to perform in a team environment.
  • Ability to travel as necessary to clinical centers to establish and manage clinical studies.
  • Minimum Bachelor’s Degree in Nursing (a Master’s Degree in Nursing is also accepted for candidates who did not complete an undergraduate nursing program).
  • Travel of 25% or more of the time
Responsibilities
  • Coordinate project deliverables such as team meetings, project budgets and timelines, and systems to track study metrics.
  • Assist Clinical Management with the development and planning of clinical study strategies, design, protocols, and other study-related documents and tools.
  • Oversee and provide clinical input for the design of the Case Report Forms and electronic databases.
  • Assist with and coordinate preparation of regulatory applications, amendments, questions from the authorities, supplements, reports, and advisory panel presentations needed to conduct studies and approve products.
  • Assist and drive clinical site selection, activation, management and any close-out activities throughout the conduct of the study including all necessary documentation.
  • Prepare and give clinical presentations to physicians, clinical study staff, agents and distributors, as required.
  • Monitor or co-monitor clinical study sites to ensure compliance with the approved study protocol, plans and objectives which may include reviewing clinical monitoring reports.
  • Assure clinical studies are adequately managed to meet the protocol objectives and schedules.
  • If applicable, support Data Monitoring Committees (Data Safety Monitoring Boards) and other committees/consultants established to support the studies.
  • Assist data management staff with clinical data review and collection of data from sites to maintain integrity by reviewing protocol deviations, adverse events, data inconsistencies, outliers, other issues as identified.
  • Develops and executes risk based study management process and plan according to study-specific risk indicators and thresholds.
  • Assist with management of study vendors for compliance to study plans, objectives and vendor contracts, including task management of labs and/or CROs, if applicable.
  • Helps to ensure sponsor and site compliance to domestic and international government regulations and guidelines.
  • Effectively communicate with LivaNova study management, participating sites, and any vendors on issues, questions and/or study updates.
  • Create, update, and maintain site administrative files and trial master files (electronic and/or paper) to ensure audit-readiness at all times.
  • Maintain accurate and up to date study tracking documents (eg enrollment, regulatory approvals and renewals, payments) and systems (eg CTMS, EDC).
  • For premarket studies, instruct warehouse and field staff in clinical device distribution and recovery. Maintain device accountability plan and report.
  • Coordinates and assists with the data review, analysis and preparation of the clinical study reports and coordinates their deliveries.
  • Coordinates closeout of sites/study, archive study documents.
Desired Qualifications
  • Experience as a Project Coordinator/Manager is a plus.

LivaNova focuses on cardiopulmonary and neuromodulation medical technologies, delivering devices and therapies for heart and brain conditions. Its products, used in hospitals worldwide, include implants and related treatments that aim to improve patient health while providing clinical and economic value to healthcare systems. The company differentiates itself with a diverse, integrated portfolio backed by decades of experience and a global reach, aligning clinical outcomes with economic impact. Its goal is to improve patients’ lives by delivering meaningful health benefits and helping providers achieve better value.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

London, United Kingdom

Founded

2015

Simplify Jobs

Simplify's Take

What believers are saying

  • Next-generation aura6000 with MRI compatibility and 15-year battery launches 2026.
  • Medicare coverage application for VNS treatment-resistant depression supported by five peer-reviewed studies.
  • Debt reduction to $377M enables M&A and R&D investment for innovation.

What critics are saying

  • Third-party component supply constraints limit Essenz production despite capacity expansion plans.
  • $400 million litigation payment Q3 2026 reduces cash reserves by approximately 50%.
  • Cardiopulmonary 18.3% Q1 2026 growth unsustainable; normalization triggers analyst downgrades.

What makes LivaNova unique

  • Essenz heart-lung machine revenue exceeded 20% growth in Q3 2025 with China expansion.
  • aura6000 OSA device FDA approval positions LivaNova in underserved $2B+ market segment.
  • VNS therapy epilepsy reimbursement increased 48% January 2026, expanding addressable patient population.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at LivaNova who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Employee Stock Purchase Plan

Flexible Work Hours

Paid Vacation

Company News

Business Wire
Mar 19th, 2026
LivaNova's aura6000 system gains FDA approval for moderate to severe obstructive sleep apnea treatment

LivaNova has received FDA premarket approval for its aura6000 System to treat adults with moderate to severe obstructive sleep apnea. The device uses proximal hypoglossal nerve stimulation for patients with an apnea-hypopnea index between 15 and 65 who cannot tolerate or have failed first-line therapies like positive airway pressure. The approval follows the OSPREY randomised controlled trial, which met its primary endpoints after six months. At 12 months, 65% of treatment patients achieved responder status, defined as at least 50% improvement from baseline and an AHI below 20. LivaNova is preparing a next-generation device for FDA submission featuring MRI compatibility, remote configuration and rechargeable battery technology lasting up to 15 years. The company plans to commercialise the advanced system next year.

Yahoo Finance
Feb 25th, 2026
LivaNova reports Q4 2025 results with fifth consecutive year of double-digit EPS growth

LivaNova, a medical device company, held its fourth-quarter and full-year 2025 earnings call, reporting strong financial performance. The company delivered double-digit revenue growth, expanded adjusted operating margins and generated robust cash flow across its cardiopulmonary and epilepsy businesses. CEO Vladimir Makatsaria highlighted that 2025 marked the company's fifth consecutive year of double-digit earnings per share growth and third straight year of double-digit organic revenue growth. The company also made progress towards financial targets outlined at its November investor day. The earnings call included executives Vladimir Makatsaria, Chief Financial Officer Alex Shvartsburg, Chief Innovation Officer Ahmet Tezel and Vice President of Investor Relations Briana Gotlin. The company posted a complementary presentation summarising key points on its investor relations website.

Yahoo Finance
Feb 25th, 2026
LivaNova posts third consecutive year of double-digit growth, targets 80% Essence heart-lung machine placements by 2026

LivaNova, a medical technology company, reported its third consecutive year of double-digit organic revenue growth in 2025, driven by its Essence heart-lung machine and cardiopulmonary consumables. The company has issued 2026 revenue guidance of 6% to 7% growth. LivaNova is transitioning focus towards high-margin markets including obstructive sleep apnea, with clinical trial device approval expected in the first half of 2026. The epilepsy business received a boost from a 48% Medicare reimbursement increase effective January 2026. The company strengthened its balance sheet by reducing debt from $628 million to $377 million. LivaNova expects to maintain adjusted operating margins above 20% whilst increasing R&D investment. A $400 million litigation payment is anticipated in the third quarter of 2026.

PR Newswire
Feb 20th, 2026
Orrum partners with LivaNova to integrate CŌRE Insights analytics with Essenz Perfusion System

Orrum Clinical Analytics has announced a strategic partnership with LivaNova USA to integrate its CŌRE Insights analytics platform with LivaNova's Essenz Perfusion System. The collaboration will enable automatic transfer of perfusion case data from Essenz to Orrum's platform for post-operative analysis and peer benchmarking. The integration, called CoreInsights for Essenz, allows perfusion teams to access continuous data capture, clinically relevant analytics measuring adherence to hospital and national benchmarks, and actionable insights on practice patterns and performance indicators. Built within a Patient Safety Organization recognised by the US Department of Health and Human Services, the platform provides secure data visualisation and analytics across the patient care continuum. The partnership aims to support evidence-based performance improvement in cardiopulmonary bypass patient management and extracorporeal care.

BioSpace
May 1st, 2024
Livanova Reports First-Quarter 2024 Results

LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter ended March 31, 2024 and raised full-year 2024 revenue and adjusted diluted earnings per share guidance.Financial Summary and Highlights(1). First-quarter revenue of $294.9 million increased 12.0% on a reported basis and 12.4% on a constant-currency basis, as compared to the prior-year period. Excluding the impact of the Advanced Circulatory Support (ACS) segment wind down, revenue increased 13.5% on a constant-currency basis. First-quarter U.S. GAAP diluted loss per share was $0.78 and adjusted diluted earnings per share was $0.73